Dr. Steve Perrin Headshot
Report a problem with this profile
[email protected]

Dr. Steve Perrin      

Chief Executive Officer and Chief Scientific Officer at the ALS Therapy Development Institute

Steve is the Chief Executive Officer and Chief Scientific Officer at the ALS Therapy Development Institute in Cambridge, MA. Dr. Perrin is an expert in the drug development process and has nearly two decades of experience in leading preclinical and translational research efforts.

As CEO and CSO at ALS TDI, Perrin is responsible for ensuring the Institute continues to advance its mission to discover and develop effective therapeutics for ALS. ALS TDI executes the largest and most comprehensive therapeutic development effort in the world focused entirely on stopping amyotrophic lateral sclerosis.

Since coming to ALS TDI in 2007, Dr. Perrin has added new capabilities to the Institute's drug development pipeline, which now includes small molecules, gene therapy, protein biologics and stem cell projects. This multi-faceted approach is designed to meet the unmet medical need posed by ALS by considering an array of therapeutic options in a centralized manner at the Institute's high-tech research facility in Cambridge. Perrin has assembled a research team of 30 full-time professionals to execute dozens of projects based on the information the Institute has developed through gene expression and other analysis of the disease, many of which have advanced to the mid and late stages of the drug development pipeline.

In 2012, Dr. Perrin led his team in outlining the world’s first Precision Medicine Program (PMP) in ALS which opened for enrollment in 2014. The PMP aims to characterize and screen potential treatments targeting the various subgroups of ALS by combining progression data collected from patients, full genome sequencing and creating disease relevant cell lines from samples collected from participants. By rapidly deploying funds directly received from the ALS Ice Bucket Challenge, more than 250 people have enrolled in the PMP. Committed to transparency and making people with ALS real partners in research, Dr. Perrin created an online portal through which each enrollee can see their data evolve as it moves through the process.

Dr. Perrin moved into the pharmaceutical industry in 1997 holding positions at the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals and more recently as Director of Molecular Profiling at Biogen.

He earned his Ph.D. at Boston University Medical Center studying the transcriptional regulation of genes during adipocyte and myocyte differentiation.

In addition to evolving the Institute into the ALS research leader it has become today, Dr. Perrin has developed a business plan to facilitate pharmaceutical partnerships for rapid clinical development and commercialization of promising therapeutics identified at the Institute for people with ALS today.


Steve Perrin, Ph.D. Appointed Chief Executive Officer

Steve Perrin, Ph.D. was appointed chief executive officer and Maureen Lister was appointed president of the ALS Therapy Development Institute (ALS TDI) during the annual meeting of its Board of Directors. The two appointments come following the passing of Sean Scott, the Institute's previous president, due to complications from Lou Gehrig's disease (ALS) this past February ...

Related Speakers View all

More like Dr.